# MQR-4.0 — Local Epistemic Authority Constitution, Claim–Role–Scope Semantics, Research-OS Boundary, Cross-Domain Commitment Typing & First Practical Added-Value Gate

## 0. Generation-IV status
MQR-3.191 authorized:

- **MQR-4.0-R** — novel scientific-realism theory: NOT AUTHORIZED.
- **MQR-4.0-A** — constitutional identity transition: AUTHORIZED.

Generation IV therefore begins under a different telos:

> MQR is a local-methodology-respecting, cross-domain epistemic-authority constitution that governs the transition from evidence/contact state to scoped, qualified, defeasible claim commitment.

The immediate question is practical:

> Does one authority schema actually help across heterogeneous scientific domains without flattening their local semantics, and can it catch commitment-level errors not already represented in the local workflow output?

## 1. Constitutional kernel
The inherited kernel remains:

- C1 Contact
- C2 Defeat
- C3 Present State
- C4 Authority/Reality Firewall

Generation IV adds no new epistemic primitive.

It only provides a standardized serialization/interface for claim adjudication.

## 2. Authority object
For claim (C), define:

[
mathcal A_t(C)=
langle
C,D,R,E_t,Q_t,V_t
angle
]

where:

- (C): the exact claim text/content;
- (D): licensed domain/scope;
- (R): epistemic role/use;
- (E_t): current local evidence/contact/defeat state;
- (Q_t): uncertainty/risk/caveat/unresolved-burden qualification;
- (V_t): current authority verdict.

(V_t) may take values such as:

- REFUSE
- HOLD
- ASSOCIATIONAL-ONLY
- SCOPED-QUALIFIED
- RISK-QUALIFIED
- ACTION-AUTHORIZED
- PROVISIONALLY-REALIST
- REOPENED
- REVOKED

These are interface states, not a claim that all local methods share identical ontology.

### Revocation contract
Each authority object must also serialize:

[
mathcal R_t(C)=
{	ext{named conditions that force review, downgrade, reopening, or revocation}}.
]

This does not add a new epistemic coordinate.
It makes C3/live defeat operational.

## 3. Practical Added-Value Gate
MQR-3.191 froze five tests:

1. PAV-1 — Cross-domain claim-role normalization.
2. PAV-2 — Commitment ceiling detection.
3. PAV-3 — Explicit revocation semantics.
4. PAV-4 — Distinguish action/prediction usefulness from realist licensing.
5. PAV-5 — Research OS cannot emit the same claim-authority object without importing MQR semantics.

MQR-4.0 executes the first real gate.

## 4. Domain A — Clinical laboratory measurement
### Local method
Clinical laboratory metrology supplies:
- measurand definition;
- calibration/traceability;
- uncertainty budget;
- allowable uncertainty linked to clinical use;
- bias monitoring and EQA.

### Claim
Example claim type:

> "This serum-creatinine result is fit to support clinical decision role (R) in validated operating scope (D)."

### Authority object

[
mathcal A^{mathrm{lab}}=
langle
C_{mathrm{fit}},
D_{mathrm{assay}},
R_{mathrm{clinical-decision}},
E_{mathrm{traceability+MU+EQA}},
Q_{mathrm{MU/bias}},
V_{mathrm{RISK!-!QUALIFIED}}
angle.
]

### Semantic preservation
The MQR object does not replace:
- the assay model;
- allowable MU criteria;
- reference methods;
- biological-variation calculations.

The local method owns these.

MQR only records the ceiling on the resulting claim:
traceability or repeatability alone cannot be promoted into unrestricted fitness-for-purpose.

### Revocation contract
Review/revoke when:
- clinically significant bias is detected;
- recalibration or reagent/instrument changes invalidate the previous evidence state;
- the intended clinical role or scope changes;
- uncertainty exceeds the accepted budget.

### PAV contribution
The schema represents a continuous, uncertainty-bearing measurement system without requiring finite-state reduction.

## 5. Domain B — NASA model validation
### Local method
NASA-HDBK-7009B supplies:
- real-world system/problem;
- model/abstraction/assumption specification;
- referent comparison;
- validation domain;
- result uncertainty;
- caveats/robustness;
- decision-risk context.

### Claim
Example claim type:

> "Model (M) is adequate for analysis/use (R) within validation domain (D)."

### Authority object

[
mathcal A^{mathrm{NASA}}=
langle
C_{mathrm{adequacy}},
D_{mathrm{validation-domain}},
R_{mathrm{specified-analysis}},
E_{mathrm{validation+uncertainty+robustness}},
Q_{mathrm{caveats/extrapolation}},
V_{mathrm{SCOPED!-!QUALIFIED}}
angle.
]

### Semantic preservation
MQR does not decide what counts as enough validation error or physical-model fidelity.
NASA/local engineering methodology owns those judgments.

MQR prevents:
- inside-domain validation from becoming global model truth;
- one intended use from silently becoming another use;
- calibration data from laundering into independent validation;
- technical usefulness from becoming unrestricted realist commitment.

### Revocation contract
Review/revoke when:
- operating conditions move outside the validation domain;
- model assumptions fail;
- version/pipeline changes alter the system-model relation;
- new referent evidence contradicts prior validation.

## 6. Domain C — Cross-sectional social-science empirical claims
### External real-world witness
Isch et al. (2026), *Quantifying the prevalence and impact of overreaching causal claims in social science*, analysed 194,631 purely cross-sectional articles.

The study reports:
- 46.3% used causal language in titles/abstracts;
- the rate rose from about 20% around 2000 to over 60% by the 2020s;
- purely cross-sectional designs lack temporal ordering and are generally vulnerable to confounding/reverse causation unless a credible identification strategy is independently supplied;
- rewritten associational phrasing and explicit methodological notes reduced readers' causal interpretation;
- LLM summaries often amplified causal overstatement.

This is a direct commitment-level failure family:
the empirical workflow can yield a valid associational result while the title/abstract/discussion upgrades the commitment.

### Claim pair
Local empirical result:

[
C_A:quad X	ext{ is associated with }Y.
]

Overreaching communication:

[
C_C:quad X	ext{ causes/changes }Y.
]

Without a causal identification strategy:

[
E_t(C_A)
otRightarrow E_t(C_C).
]

### Authority objects

For the associational claim:

[
mathcal A^{mathrm{soc}}(C_A)=
langle
C_A,D_{mathrm{sample/design}},
R_{mathrm{association}},
E_{mathrm{cross-sectional}},
Q_{mathrm{confounding/reverse-causality}},
V_{mathrm{SCOPED!-!QUALIFIED}}
angle.
]

For the causal claim:

[
mathcal A^{mathrm{soc}}(C_C)=
langle
C_C,D_{mathrm{same}},
R_{mathrm{causal}},
E_{mathrm{cross-sectional}},
Q_{mathrm{unresolved-identification}},
V_{mathrm{HOLD/REFUSE}}
angle.
]

### Practical correction
MQR forces an output-layer correction:

> replace the causal claim with an associational claim,
> or provide an independently justified causal identification strategy.

This changes the actual statement/caveat even though the data analysis may remain unchanged.

The Nature Human Behaviour experiment provides independent evidence that wording changes matter to reader interpretation.

### PAV contribution
This satisfies the first strong practical-added-value witness:
**the error occurs at the commitment/communication layer after the local empirical workflow.**

MQR is not inventing the causal-inference principle.
Its added role is to type the final claim against the evidence role.

## 7. Domain D — Accelerated approval as a revocation test
FDA accelerated approval provides a real authority-transition witness.

FDA explicitly states:
- a surrogate endpoint may be reasonably likely to predict clinical benefit without itself measuring clinical benefit;
- confirmatory studies are required;
- approval may be withdrawn if benefit is not verified.

Pepaxto:
- accelerated approval in 2021;
- confirmatory evidence failed to verify clinical benefit;
- FDA withdrew approval in February 2024.

### Initial authority state

[
mathcal A_{2021}=
langle
C_{mathrm{regulatory-use}},
D_{mathrm{approved-population}},
R_{mathrm{conditional-action}},
E_{mathrm{surrogate-response}},
Q_{mathrm{residual-benefit-uncertainty}},
V_{mathrm{ACTION!-!AUTHORIZED}}
angle.
]

Crucially, this is not:

[
V=mathrm{FULLY!-!VERIFIED CLINICAL BENEFIT}.
]

### Successor state
After confirmatory failure:

[
mathcal A_{2024}
	o
V_{mathrm{REVOKED}}.
]

### PAV contribution
This demonstrates explicit revocation semantics without conflating:
- action authority;
- clinical-benefit epistemic commitment;
- final realist claim.

## 8. Cross-domain normalization result
The same interface can encode four non-isomorphic domains:

| Domain | Local epistemic object | MQR role |
|---|---|---|
| Clinical laboratory | measurement + MU | fitness-for-use ceiling |
| NASA M&S | validated model/domain | scoped model-use ceiling |
| Social science | associational empirical relation | causal-language ceiling |
| FDA accelerated approval | conditional regulatory evidence | action-vs-benefit authority + revocation |

The local evidence structures remain different.

MQR normalizes only:
- claim;
- scope;
- role;
- evidence state;
- qualification;
- authority verdict;
- revocation condition.

Therefore:

**PAV-1 CROSS-DOMAIN NORMALIZATION = PASS.**

No semantic flattening was required in the tested examples.

## 9. Commitment ceiling result
The Isch et al. corpus supplies a real failure family where:
- local data analysis can remain unchanged;
- title/abstract/discussion commitment exceeds the evidence role;
- rewriting the claim reduces causal misinterpretation.

This is exactly the layer MQR-A was designed to adjudicate.

Therefore:

**PAV-2 COMMITMENT CEILING = PASS.**

Important limitation:
causal-overclaim detection is not unique to MQR.
The added value is standardized claim/evidence-role adjudication across domains, not a novel causal methodology.

## 10. Revocation semantics result
The FDA/Pepaxto transition shows that:

[
	ext{ACTION-AUTHORIZED}
	o
	ext{REVOKED}
]

can be represented without pretending that the initial action authorization was equivalent to full clinical-benefit verification.

NASA scope exit and laboratory bias detection provide analogous review transitions.

Therefore:

**PAV-3 REVOCATION SEMANTICS = PASS.**

## 11. Usefulness vs realist commitment
Generation IV must preserve:

[
	ext{useful/actionable}

otRightarrow
	ext{realistically established}.
]

Examples:
- accelerated approval can be action-authorized while clinical benefit remains unverified;
- a model can be adequate for a bounded engineering decision without being a globally true representation;
- a measurement can be fit for a specified decision role without fixing an exact world state.

Therefore:

**PAV-4 USEFULNESS–REALISM SEPARATION = PASS.**

## 12. Research OS boundary stress
Research OS 2.4.4 can already:
- detect authority laundering;
- track evidence topology;
- trigger recontact;
- preserve scope/provenance;
- separate search success from scientific authority.

Therefore MQR cannot claim that only it can notice the above problems.

The narrower difference is output contract.

### Research OS output
Primarily:
- frontier/search state;
- operator/diagnostic recommendation;
- evidence/recontact plan;
- data-need certificate.

### MQR output
A normalized claim-authority object:

[
(C,D,R,E_t,Q_t,V_t,mathcal R_t).
]

Research OS could emit this only by importing a claim-commitment semantics equivalent to MQR-A.

However this is currently an architectural distinction, not yet a demonstrated productivity advantage.

Therefore:

**PAV-5 RESEARCH-OS NONREDUNDANCY = PASS-NARROW / EMPIRICAL PRODUCTIVITY HOLD.**

## 13. Bureaucracy test
The authority object must remain compact.

Minimal required fields:
1. claim;
2. scope;
3. role;
4. local evidence-state reference;
5. qualification;
6. verdict;
7. revocation/review trigger.

MQR must not reproduce the local technical report.

### Practical rule
If completing the authority object requires rebuilding the domain analysis, MQR has failed.

The target is a thin typed boundary object over already-existing local evidence.

Current examples can be represented compactly.

Therefore:

**BUREAUCRACY FEASIBILITY = PASS-PRELIMINARY.**

No quantitative cost–benefit result is yet available.

## 14. First Generation-IV gate
Results:

- PAV-1 cross-domain normalization: PASS.
- PAV-2 commitment ceiling: PASS.
- PAV-3 revocation semantics: PASS.
- PAV-4 usefulness vs realism: PASS.
- PAV-5 Research OS nonredundancy: PASS-NARROW.
- bureaucracy/error-cost advantage: PRELIMINARY ONLY.

This is enough to justify **continued independent Generation-IV probation**.

It is not enough to declare the architecture permanently independent.

## 15. Literature pressure
Current literature prevents inflated novelty claims.

Menon (2026) already frames scientific realism in normative terms centred on authority and domain-specific agent-first strategies.

Mayne (2026) argues realism operationalization should often be local rather than imposed by one unified global ontological principle.

Brousalis (2026) shows that disciplinary diversity creates a nontrivial localism/globalism problem rather than straightforwardly licensing universal or purely local principles.

Therefore Generation IV's distinctive claim is practical/architectural:

> a thin, cross-domain claim-authority interface layered over sovereign local methodologies.

Not:
> the discovery of authority, locality, or pragmatist realism as philosophical ideas.

## 16. Generation-IV status
### Authorized
MQR-4.0-A is now materially instantiated.

### Still prohibited
- no "new realism theory" claim;
- no local-methodology replacement;
- no duplication of Research OS;
- no authority object generated without domain evidence;
- no claim that PAV-2 error detection is methodologically unique to MQR.

### Survival condition
Generation IV remains independent only if subsequent stages show:
- reproducible claim-level audits;
- low overhead;
- useful corrections in real workflows;
- authority objects that native Labs or Research OS can consume without semantic loss.

## 17. Verdict
**PASS-GENERATION-IV-MATERIALIZATION / LOCAL-EPISTEMIC-AUTHORITY-CONSTITUTION-ACTIVE / FOUR-DOMAIN-COMMITMENT-TYPING / PAV-1-PASS / PAV-2-PASS / PAV-3-PASS / PAV-4-PASS / PAV-5-PASS-NARROW / REAL-CAUSAL-OVERCLAIM-COMMITMENT-CEILING-WITNESS / FDA-REVOCATION-WITNESS / RESEARCH-OS-BOUNDARY-RETAINED / BUREAUCRACY-FEASIBILITY-PRELIMINARY / INDEPENDENT-G4-STATUS-PROBATIONARY / NO-MQR-4.0-R.**
